Traws Pharma, Inc. — fact timeline

Traws Pharma, Inc. reported for the quarter ended March 31, 2026 results: revenue $0.0 million, net income $7.1 million, EPS $0.53.

“milestone-based warrants, is sufficient to support planned expenses, including completion of the Challenge Study, into Q1 2027. Revenue for the quarter ended March 31, 2026, was $0.0 million, compared to $0.06 million for the comparable period in 2025. Research and development (R&D) expense for the quarter ended March 31, 2026, totaled $4.9 million, compared to $2.5”

Traws Pharma, Inc. issued 5,982,919 shares of common stock to Institutional and accredited investors for $1.6730 per share for each Purchased Share and accompanying Series A, B, and C Warrants ($1.6630 for Pre-Funded Warrant).

“a Phase 2a human challenge trial in the United Kingdom. The purchase price per each Purchased Share and accompanying Series A Warrant, Series B Warrant, and Series C Warrant was $1.6730. The purchase price per each Pre-Funded Warrant and accompanying Series A Warrant, Series B Warrant, and Series C Warrant was $1.6630, and each Pre-Funded Warrant has an exercise”

Traws Pharma, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $10,000,000 (effective 2026-04-15).

“On April 15, 2026, Traws Pharma, Inc. (the “Company”) announced the pricing of an offering (the “Private Placement”) of an aggregate of (i) 5,982,919 shares (the “Purchased Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”) (or, in lieu of Purchased Shares, pre-funded warrants to purchase shares of Common Stock (“Pre-Funded Warrants”)), (ii) Series A warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series A Warrants”), (iii) Series B warrants to initially purchase up to 5,982,919 shares of Common Stock (the “Series B Warrants”), and (iv) Series C warrants to initially purchase up to 17,948,757 shares of Common Stock (the “Series C Warrants” and together with the Pre-Funded Warrants, the Series A Warrants and the Series B Warrants, the “Warrants”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and the purchasers named therein (the “Investors”).”

Traws Pharma, Inc. completed an acquisition involving Virom, Inc. for $2,350,000 in cash (closed 2025-09-09).

“On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.”

Iain Dukes was appointed as Interim Chief Executive Officer at Traws Pharma, Inc..

“Effective as of the Termination Date, the Board appointed Iain Dukes to serve as the Company’s Interim Chief Executive Officer.”

Werner Cautreels resigned as Chief Executive Officer at Traws Pharma, Inc..

“On March 28, 2025, Werner Cautreels notified Traws Pharma, Inc. (the Company”) of his decision to retire and resign from his role as Chief Executive Officer of the Company, effective as of the close of business on the day that the Company files its Annual Report on Form 10-K for its 2024 fiscal year”

Nora Brennan was appointed as Interim Chief Financial Officer at Traws Pharma, Inc..

“On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.”

Mark Guerin resigned as Chief Financial Officer at Traws Pharma, Inc..

“On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.”

Luba Greenwood was appointed as Director at Traws Pharma, Inc..

“the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.”

James J. Marino resigned as Director at Traws Pharma, Inc..

“On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.”

Steven M. Fruchtman resigned as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..

“On June 17, 2024, Steven M. Fruchtman informed the board of directors (the “Board”) of Traws Pharma, Inc. (the “Company”) of his intent to resign from his positions of President and Chief Scientific Officer, Oncology.”

Traws Pharma, Inc. reported the first quarter of 2024 results: revenue fifty-six thousand dollars, net income $5.0 million, or $0.24 per share, EPS $0.24 per share.

“Revenue was fifty-six thousand dollars for the first quarter of 2024, consistent with the same period in 2023.”

Traws Pharma, Inc.: Changed company name to Traws Pharma, Inc. via certificate of amendment to Tenth Amended and Restated Certificate of Incorporation on April 2, 2024 (effective 2024-04-02).

“On April 2, 2024, the Company changed its name to Traws Pharma, Inc. pursuant to a certificate of amendment to its Tenth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).”

Traws Pharma, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock on April 1, 2024 (effective 2024-04-01).

“On April 1, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Merger referenced in Item 1.01 above.”

Traws Pharma, Inc. completed an acquisition involving Trawsfynydd Therapeutics, Inc. for 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock (closed 2024-04-01).

“shares of capital stock of Trawsfynydd immediately prior to the effective time of the First Merger, the Company issued to the stockholders of Trawsfynydd an aggregate of (A) 3,549,538 shares of common stock of the Company, par value $0.01 per share (the “Common Stock”) and (B) 10,359.0916 shares of Series C Preferred Stock (as defined and described below). Each”

Robert Redfield was appointed as Chief Medical Officer at Traws Pharma, Inc..

“In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.”

C. David Pauza was appointed as Chief Scientific Officer, Virology at Traws Pharma, Inc..

“In addition, effective immediately upon the Closing, C. David Pauza was appointed the Company’s Chief Scientific Officer, Virology and Robert Redfield was appointed the Company’s Chief Medical Officer.”

Werner Cautreels was appointed as Chief Executive Officer at Traws Pharma, Inc..

“appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO”

Nikolay Savchuk was appointed as Chief Operating Officer at Traws Pharma, Inc..

“appointed Werner Cautreels as the Company’s CEO and Nikolay Savchuk as the Company’s COO”

Iain Dukes was appointed as Executive Chairman at Traws Pharma, Inc..

“appointed Iain Dukes as a director and Executive Chairman of the Company”

Mark Guerin departed as Chief Financial Officer at Traws Pharma, Inc..

“Mark Guerin remained as the Chief Financial Officer of the Company”

Steven M. Fruchtman was appointed as President and Chief Scientific Officer, Oncology at Traws Pharma, Inc..

“Dr. Steven M. Fruchtman remained as the President of the Company and was appointed Chief Scientific Officer, Oncology”

Viren Mehta resigned as Director at Traws Pharma, Inc..

“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”

Jerome Groopman resigned as Director at Traws Pharma, Inc..

“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”

Peter Atadja resigned as Director at Traws Pharma, Inc..

“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”

Steven M. Fruchtman resigned as Director at Traws Pharma, Inc..

“accepted the resignations of Dr. Steven M. Fruchtman, Peter Atadja, Jerome Groopman, and Viren Mehta from the Board”

Traws Pharma, Inc. reported third quarter 2023 results: net income Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs, EPS $0.23 per share.

“Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outstanding”

Traws Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 25, 2023, the Company received a letter from The Nasdaq Capital Market (“Nasdaq”) indicating that the Company has failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a) (2) requires that companies listed on Nasdaq maintain a minimum closing bid price of at least $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180 calendar day grace period, or until March 25, 2024, to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the Company’s common”

Traws Pharma, Inc. shareholders approved To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-08-10 meeting.

“Proposal 3. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 9,271,526 368,397 875,093 -”

Traws Pharma, Inc. shareholders approved To approve, on an advisory basis, the compensation of our named executive officers. at the 2023-08-10 meeting.

“Proposal 2. To approve, on an advisory basis, the compensation of our named executive officers. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 4,959,016 1,066,808 900,578 3,588,614”

Traws Pharma, Inc. shareholders approved To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. at the 2023-08-10 meeting.

“Proposal 1. To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows: Nominee For Withheld Broker Non-Votes James J. Marino 5,541,973 1,384,429 3,588,614 Steven M. Fruchtman 5,555,005 1,371,397 3,588,614 Peter Atadja 5,670,083 1,256,319 3,588,614 Trafford Clarke 5,541,659 1,384,743 3,588,614 Jerome E. Groopman 5,537,395 1,389,007 3,588,614 Viren Mehta 5,570,427 1,355,975 3,588,614 M. Teresa Shoemaker 5,592,043 1,334,359 3,588,614 Jack E. Stover 5,559,133 1,367,269 3,588,614”

Traws Pharma, Inc. reported the quarter and six months ended June 30, 2023 results: net income $4.3 million, EPS $0.20 per share.

“Net loss for the second quarter of 2023 was $4.3 million, or $0.20 per share on 21.0 million weighted shares outstanding, compared with a net loss of $4.0 million, or $0.19 per share for the second quarter of 2022 on 20.9 million weighted shares outstanding.”

Traws Pharma, Inc. reported the three months ended March 31, 2023 results: net income $5.8 million, EPS $0.28 per share.

“Net loss for the first quarter of 2023 was $5.8 million, or $0.28 per share on 20.9 million weighted shares outstanding, compared with a net loss of $4.1 million, or $0.20 per share for the first quarter of 2022 on 20.9 million weighted shares outstanding.”

Traws Pharma, Inc. reported the twelve months ended December 31, 2022 results: net income $19.0 million, EPS $0.91 per share.

“Net loss for 2022 was $19.0 million, or $0.91 per share on 20.9 million weighted average shares outstanding, compared with a net loss of $16.2 million, or $0.96 per share for 2021 based on 16.8 million weighted average shares outstanding.”

Trafford Clarke was elected as Director at Traws Pharma, Inc..

“elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.”

Peter Atadja was elected as Director at Traws Pharma, Inc..

“elected Peter Atadja, Ph.D. and Trafford Clarke, Ph.D. as members of the Board, effective immediately.”

Traws Pharma, Inc. reported financial results for the quarter ended September 30, 2022.

“On November 14, 2022, Onconova Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.”

Abraham N. Oler resigned as Senior Vice President, Corporate Development and General Counsel at Traws Pharma, Inc..

“On June 10, 2022, Abraham N. Oler, Senior Vice President, Corporate Development and General Counsel, notified the company of his resignation effective June 17, 2022 to pursue an opportunity outside the biotechnology sector.”

Mark Guerin was appointed as Chief Operating Officer at Traws Pharma, Inc..

“On June 10, 2022, Onconova Therapeutics, Inc. (the “Company”) appointed Mark Guerin, as Chief Operating Officer in addition to his current role as Chief Financial Officer.”